Skip to main content

Sjogren's Syndrome

14
Pipeline Programs
15
Companies
11
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
3
7
0
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
660%
Monoclonal Antibody
440%
+ 8 programs with unclassified modality

Competitive Landscape

13 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
5 programs
3
1
1
RituximabPhase 4Monoclonal Antibody1 trial
BaricitinibPhase 2Small Molecule
68Ga-FAPIPhase 1/21 trial
Baricitinib 2 MGPhase 1/21 trial
IguratimodPhase 1/21 trial
Active Trials
NCT07062523Recruiting60Est. Dec 2025
NCT04916756Completed11Est. Mar 2021
NCT03023592Unknown30Est. Apr 2018
+1 more trials
Alcon
AlconFORT WORTH, TX
2 programs
1
MaxidexPhase 41 trial
FID 114657N/A1 trial
Active Trials
NCT01079871Completed50
NCT00631358Completed97
Prevail Therapeutics
1 program
1
BaricitinibPhase 2Small Molecule
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
BelimumabPhase 2Monoclonal Antibody
Sandoz
SandozAustria - Kundl
1 program
1
IscalimabPhase 2Monoclonal Antibody
Ono Pharmaceutical
Ono PharmaceuticalJapan - Osaka
1 program
1
LanraplenibPhase 2Small Molecule1 trial
Active Trials
NCT03100942Completed152Est. Oct 2019
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
LanraplenibPhase 2Small Molecule
Resolve Therapeutics
1 program
1
RSLV-132Phase 21 trial
Active Trials
NCT03247686Completed28Est. Aug 2019
Rise Therapeutics
Rise TherapeuticsMD - Rockville
1 program
1
R-2487Phase 11 trial
Active Trials
NCT06297213Not Yet Recruiting36Est. Aug 2028
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
RituximabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT00101829Completed12Est. Aug 2009
Dompé
DompéItaly - L'Aquila
1 program
Eye ExamN/A1 trial
Active Trials
NCT06364657Terminated13Est. Dec 2024
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
LanraplenibPHASE_2Small Molecule
Galapagos
Galapagos2800 MECHELEN, Belgium
1 program
LanraplenibPHASE_2Small Molecule

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
UNION therapeuticsRituximab
AlconMaxidex
Ono PharmaceuticalLanraplenib
Resolve TherapeuticsRSLV-132
UNION therapeutics68Ga-FAPI
UNION therapeuticsBaricitinib 2 MG
UNION therapeuticsIguratimod
Rise TherapeuticsR-2487
Allergy TherapeuticsRituximab
DompéEye Exam
AlconFID 114657

Clinical Trials (11)

Total enrollment: 504 patients across 11 trials

NCT06410833UNION therapeuticsRituximab

Belimumab After Rituximab in Resistant Primary Juvenile SS

Start: Mar 2024Est. completion: Dec 202615 patients
Phase 4Recruiting
NCT00631358AlconMaxidex

Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention

Start: Feb 200897 patients
Phase 4Completed
NCT03100942Ono PharmaceuticalLanraplenib

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

Start: May 2017Est. completion: Oct 2019152 patients
Phase 2Completed
NCT03247686Resolve TherapeuticsRSLV-132

A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome

Start: Feb 2017Est. completion: Aug 201928 patients
Phase 2Completed
NCT07062523UNION therapeutics68Ga-FAPI

Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT

Start: Jul 2024Est. completion: Dec 202560 patients
Phase 1/2Recruiting
NCT04916756UNION therapeuticsBaricitinib 2 MG

A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients

Start: Jan 2020Est. completion: Mar 202111 patients
Phase 1/2Completed
NCT03023592UNION therapeuticsIguratimod

Study of Iguratimod in Sjögren's Syndrome

Start: Feb 2017Est. completion: Apr 201830 patients
Phase 1/2Unknown
NCT06297213Rise TherapeuticsR-2487

R-2487 in Patients With Sjogren's Syndrome (SS)

Start: Jun 2026Est. completion: Aug 202836 patients
Phase 1Not Yet Recruiting
NCT00101829Allergy TherapeuticsRituximab

Anti-CD20 Antibody Therapy for Sjogren's Syndrome

Start: Apr 2004Est. completion: Aug 200912 patients
Phase 1Completed
NCT06364657DompéEye Exam

Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye

Start: Jul 2024Est. completion: Dec 202413 patients
N/ATerminated
NCT01079871AlconFID 114657

Evaluation of FID 114657 in Sjogren's Syndrome Subjects

Start: Feb 201050 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 504 patients
15 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.